Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Therapeutic cancer vaccine to target tumour specific mutations identified by whole transcriptome shotgun sequencing
EF 2010-11
Résumé
A hallmark of cancer is the accumulation of mutations, or changes in the genetic code, that allow cancer cells to grow and multiply uncontrollably. Each individual tumour contains a unique set of mutations. Recent technological advances in genetic sequencing have dramatically lowered the cost of identifying these mutations so we can now identify all mutations in a patient's tumour. The next major challenge is to develop clinically feasible, cost-effective strategies to therapeutically target the complex mutational landscape of human cancer.
The immune system recognizes and destroys cells that are abnormal due to infection or mutation. However, in the case of cancer, the immune system seems to ignore many mutations so tumours are able to grow and spread. I hypothesize we can use vaccines to fully activate the immune system to recognize mutations and destroy tumours.
We used next generation sequencing technology to find 59 candidate mutations in a mouse breast tumour. In Aim 1, we will use software to predict which of the mutations are likely to be immunogenic (i.e., recognized by the immune system). We will develop vaccines made of small segments of proteins that mimic the immunogenic mutations to activate the immune system specifically against the mutations. In Aim 2, we will implant tumour cells containing these mutations into mice. We will then vaccinate mice and measure the level of immune system activation. We expect vaccination to elicit a potent immune response that will lead to tumour regression.
If successful, this project will pave the road to a new form of cancer treatment. As the cost of sequencing an entire human genome approaches the $1000 mark, we and others believe it will become feasible to routinely subject patients' tumours to genomic sequencing. We propose the mutations identified by sequencing could be used to design personalized vaccines that trigger a patient's immune system to recognize and destroy cancer cells throughout the body.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
226946
Name
Martin Spencer
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Therapeutic cancer vaccine to target tumour specific mutations identified by whole transcriptome shotgun sequencing
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjuvants; Cancer Immunotherapy; Epitope Prediction; Epitopes; Genetic Mutations; Immune Evasion; T Cells; Tumorigenesis; Vaccine; Whole Transcriptome Shotgun Sequencing
Abstract
A hallmark of cancer is the accumulation of mutations, or changes in the genetic code, that allow cancer cells to grow and multiply uncontrollably. Each individual tumour contains a unique set of mutations. Recent technological advances in genetic sequencing have dramatically lowered the cost of identifying these mutations so we can now identify all mutations in a patient's tumour. The next major challenge is to develop clinically feasible, cost-effective strategies to therapeutically target the complex mutational landscape of human cancer.
The immune system recognizes and destroys cells that are abnormal due to infection or mutation. However, in the case of cancer, the immune system seems to ignore many mutations so tumours are able to grow and spread. I hypothesize we can use vaccines to fully activate the immune system to recognize mutations and destroy tumours.
We used next generation sequencing technology to find 59 candidate mutations in a mouse breast tumour. In Aim 1, we will use software to predict which of the mutations are likely to be immunogenic (i.e., recognized by the immune system). We will develop vaccines made of small segments of proteins that mimic the immunogenic mutations to activate the immune system specifically against the mutations. In Aim 2, we will implant tumour cells containing these mutations into mice. We will then vaccinate mice and measure the level of immune system activation. We expect vaccination to elicit a potent immune response that will lead to tumour regression.
If successful, this project will pave the road to a new form of cancer treatment. As the cost of sequencing an entire human genome approaches the $1000 mark, we and others believe it will become feasible to routinely subject patients' tumours to genomic sequencing. We propose the mutations identified by sequencing could be used to design personalized vaccines that trigger a patient's immune system to recognize and destroy cancer cells throughout the body.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Martin, Spencer
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~